“Lombard represents a unique opportunity given the strength of the company’s portfolio in the over $1.5 billion market for endovascular repair products. The key to success will be our ability to leverage the work that has been done over the years and moreover, to achieve operational excellence. For my part, I am committed to creating value for all of the stakeholders of Lombard,” Lemvigh said in a prepared statement.
“Simon made many significant contributions during his six years as CEO of Lombard including expanding the company’s product portfolio and geographic reach. On behalf of the board and shareholders, we thank Simon for his contributions and diligent efforts during a time of significant change in the endovascular aneurysm repair market. We wish him well in his future endeavors,” board chair Raymond Cohen said in a press release.
Kullback’s resignation was part of the company’s discontinuation of commercial operations in the US, the company said, and not the result of any disagreements with the company. Kullback will be moving on to “pursue a new opportunity at a San Diego, Calif.-based company,” according to an SEC filing.
With the shift, Polen will oversee all of BD’s operating segments, including medical, life sciences and the new interventional segment formed when it agreed to pick up Bard in a $24 billion deal.
“Tom brings a deep understanding of BD, the medical technology industry and the global healthcare environment. His well-deserved promotion reflects his leadership in developing and implementing BD Medical’s strategy and vision, his proven track record of delivering strong performance, and his commitment to ensuring the ongoing success of BD and its associates. I look forward to continuing to work closely with the Board, Tom, our entire leadership team, and our associates to successfully integrate and grow the combined company in the years ahead, as we deliver on our purpose of advancing the world of health,” CEO & chair Vince Forlenza said in a press release.
“This is an exciting time for BD. I am honored to serve in this new role as we continue our transformation into a medical technology leader focused on delivering solutions that advance the discovery, diagnostics and delivery of health care globally and helping health care providers worldwide to improve both the process of care and the treatment of disease,” Polen said in a prepared statement.
Prior to his position as head of USGI, Babini served as VP of AirSeal system commercialization at ConMed, chief commercialization officer at Surgiquest and various other executive positions in medtech.
“I am delighted to join USGI Medical at this critical time as the company continues to establish the Pose procedure as a credible option for clinicians who have patients seeking clinical assistance to achieve weight loss. This procedure has the potential to help millions of obese patients globally who have not been able to keep weight off through diet and exercise alone, and who may not be candidates for, nor able to undertake the possible risks associated with invasive bariatric surgery,” Babini said in a prepared statement.
“I have had the pleasure of working with Mr. Babini during this initial period and in a very short time, already experienced positive momentum and engagement with the entire USGI team,” former CEO & current exec chair Scott Moonly said in a press release.
Fresenius CEO Sturm, who was promoted to CFO last June, said earlier this week that the company had found someone for its CFO position, but did not clarify when their current employer would let them go.
Negotiations for the move are in their final stage, the magazine said. A spokesperson for Fresenius would not comment on the report.
Pratt jointed Boston Scientific in May 2008 as an exec VP, GC and secretary. Over the next several months, Pratt said he intends to lead the effort to find a successor and aid in a transition to the new GC.